Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ6 | P48051 | 17/20 | 0.69 |
| ▸ | KCNJ3 | P48549 | 17/20 | 0.69 |
| ▸ | KCNJ5 | P48544 | 13/20 | 0.69 |
| ▸ | BRAF | P15056 | 2/20 | 0.56 |
| ▸ | RAF1 | P04049 | 1/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4303949 | 0.92 | KCNJ6 (0.58) | KCNJ6KCNJ3KCNJ5BRAFRAF1 | |
| SCHEMBL4300985 | 0.80 | KCNJ6 (0.50) | KCNJ6KCNJ3KCNJ5BRAFNTRK1 | |
| SCHEMBL4647983 | 0.79 | KCNJ6 (0.66) | KCNJ6KCNJ3KCNJ5BRAF | |
| SCHEMBL1896470 | 0.78 | KDR (0.73) | BRAF | |
| SCHEMBL4936063 | 0.78 | KCNJ6 (1.00) | KCNJ6KCNJ3KCNJ5BRAF | |
| SCHEMBL4937639 | 0.77 | KCNJ6 (0.80) | KCNJ6KCNJ3KCNJ5BRAF | |
| SCHEMBL13234482 | 0.77 | KCNJ6 (0.84) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL13234630 | 0.77 | KCNJ6 (0.75) | KCNJ6KCNJ3KCNJ5BRAF | |
| SCHEMBL13234480 | 0.76 | KCNJ6 (0.76) | KCNJ6KCNJ3KCNJ5BRAF | |
| SCHEMBL2082434 | 0.75 | KCNJ6 (0.49) | KCNJ6KCNJ3KCNJ5BRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131437-A1 | DISUBSTITUTED UREAS AS KINASE INHIBITORS | CORIUM INTERNATIONAL, INC. (US) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131437-A1 | DISUBSTITUTED UREAS AS KINASE INHIBITORS | UCK2, ULK2, MAP3K1 | KCNJ6 1465/4885KCNJ3 1539/4885KCNJ5 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.